0
Bioprosthetic Valve
Degeneration
Philipp Emanuel Bartko, MD and
Jutta Bergler-Klein, MD
Med. Univ. of Vienna, Dept. Of
Car...
Clinical Presentation and Medical History
 76 year old female
 Seen at the outpatient clinic for general fatigue, atypic...
Clinical and biological Findings
 Physical examination:
• 159 cm, 58 kg
• Blood pressure 150/90 mmHg; 78 bpm
• Loud systo...
Transthoracic Echocardiography
Watch video

Watch video
Transthoracic Echocardiography Report
 Bioprosthetic aortic valve
• Significantly thickened cusps
• Trivial central prost...
Compare to Discharge Echo after Valve Surgery
 At discharge in 2007:
• Aortic peak velocity 2.51m/sec
• Mean gradient 11 ...
Transoesophageal Echocardiography
Watch video

Watch video

Watch video

Watch video
Transoesophageal Echocardiography Conclusion

• Degenerating bioprosthetic valve
with fixed cusps and reduced
valve area
•...
Echocardiographic Assessment of Prosthetic Valves
What should you know in advance?
 Valve type
• Bioprosthetic valve: ste...
Echocardiographic Assessment of Prosthetic Valves
What to Report - I

 Date of surgery
 Type of valve prosthesis
 Heigh...
Echocardiographic Assessment of Prosthetic Valves
What to Report -II

 Valve
• Seating (Abnormal motion? Tilting, Rocking...
Structural Valve Degeneration
 Structural valve degeneration is the major cause of
bioprosthetic valve failure
 Age depe...
Summary
 Echocardiography with Doppler is the method of choice in the
evaluation and follow up of patients with valve pro...
Join the ESC Working Group
on Valvular Heart Disease
and take part in its
activities !
Membership is FREE!
Upcoming SlideShare
Loading in...5
×

Bioprosthetic Valve Degeneration

474

Published on

Published in: Health & Medicine
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
474
On Slideshare
0
From Embeds
0
Number of Embeds
3
Actions
Shares
0
Downloads
32
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide
  • <number>
  • <number>
  • <number>
  • <number>
  • <number>
  • <number>
  • <number>
  • <number>
  • <number>
  • <number>
  • <number>
  • <number>
  • <number>
  • <number>
  • Transcript of "Bioprosthetic Valve Degeneration"

    1. 1. Bioprosthetic Valve Degeneration Philipp Emanuel Bartko, MD and Jutta Bergler-Klein, MD Med. Univ. of Vienna, Dept. Of Cardiology, Vienna, Austria jutta.bergler-klein@meduniwien.ac.at
    2. 2. Clinical Presentation and Medical History  76 year old female  Seen at the outpatient clinic for general fatigue, atypical chest pain, dizziness and dyspnoea on exertion for several months.  No syncope or recent fever  She underwent cardiac surgery in 2007 • Replacement of the aortic valve using a Mitroflow 21mm (stented bovine pericardial valve) and aortic root for severe aortic stenosis with calcified bicuspid aortic valve and aneurysm of the ascending aorta • Single coronary artery bypass graft (LIMA to LAD) • Tricuspid valve annuloplasty with ring implantation  Paroxysmal atrial fibrillation
    3. 3. Clinical and biological Findings  Physical examination: • 159 cm, 58 kg • Blood pressure 150/90 mmHg; 78 bpm • Loud systolic heart murmur at 2nd right intercostal space with transmission to the carotid arteries • No peripheral oedema  ECG • Sinus rhythm • Non-specific ST wave alterations • LV hypertrophy  Biology • Normal CRP, creatinine and thyroid hormones levels • NT-proBNP 213 pg/ml
    4. 4. Transthoracic Echocardiography Watch video Watch video
    5. 5. Transthoracic Echocardiography Report  Bioprosthetic aortic valve • Significantly thickened cusps • Trivial central prosthetic regurgitation • Doppler parameters • Peak jet velocity 3.8m/sec • Mean aortic gradient 37 mmHg • Effective orifice area 1.1 cm² (0.7 cm²/m² of body surface area)  Left ventricle • • • • Normal ejection fraction No regional wall motion abnormalities End diastolic volume 99mL Stroke volume: 72ml (46ml/m²) by Simpson method, 79ml (50ml/m²) by Doppler method
    6. 6. Compare to Discharge Echo after Valve Surgery  At discharge in 2007: • Aortic peak velocity 2.51m/sec • Mean gradient 11 mmHg • Effective orifice area 1.7 cm²  Increasing aortic valve gradient Bioprosthetic Degeneration? Patient-Prosthesis Mismatch? Exact prosthesis morphology  TEE
    7. 7. Transoesophageal Echocardiography Watch video Watch video Watch video Watch video
    8. 8. Transoesophageal Echocardiography Conclusion • Degenerating bioprosthetic valve with fixed cusps and reduced valve area • The patient was referred for redo surgery
    9. 9. Echocardiographic Assessment of Prosthetic Valves What should you know in advance?  Valve type • Bioprosthetic valve: stented, stentless or sutureless • Mechanical valve: bileaflet, tilting disc or ball in cage  Valve size • May cause differences in gradients and effective orifice area  BSA of the patient • Calculation of the indexed effective orifice area to assess potential patient / prosthesis mismatch  Year of implantation • Median time to reoperation for structural valve deterioration is agedependent and varies from average 11 years in a 20-y old, to 25 years in a 65-y old.  Additional surgical interventions • Coronary bypass grafts, other valve surgery  Smedira NG, Blackstone EH, Roselli EE et al. J Thorac Cardiovasc Surg 2006;131:558-64  El-Hamamsy I, Clark L, Stevens LM et al. J Am Coll Cardiol 2010;55:368-76
    10. 10. Echocardiographic Assessment of Prosthetic Valves What to Report - I  Date of surgery  Type of valve prosthesis  Height, weight, BSA of patient  Blood pressure, heart rate  Haemodynamic conditions: left ventricular size and function, stroke volume (index)  Vahanian A, Alfieri O, Andreotti F et al. Guidelines on the management of valvular heart disease (version 2012). Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC); European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2012;33(19):2451-96
    11. 11. Echocardiographic Assessment of Prosthetic Valves What to Report -II  Valve • Seating (Abnormal motion? Tilting, Rocking?) • Leaflets or occluder motion • Morphology (Calcification? Abnormal echo densities? Valve sewing ring? Ring integrity?) • Doppler: Peak jet velocity, peak and mean gradient, effective orifice area  compare to specified prosthesis normal values • Regurgitation (degree, para- or intravalvular location, mechanism) A TTE should be performed at discharge or 30 days after surgery and will serve as a future reference  Zoghbi WA, Chambers JB, Dumesnil JG et al. Recommendations for evaluation of prosthetic valves with echocardiography and doppler ultrasound. J Am Soc Echocardiogr 2009;22:975-1014  Daneshvar SA, Rahimtoola SH. Valve prosthesis-patient mismatch: a long-term perspective. J Am Coll Cardiol 2012 Sep 25;60(13):1123-35
    12. 12. Structural Valve Degeneration  Structural valve degeneration is the major cause of bioprosthetic valve failure  Age dependent, it occurs early in young patients.  Lipid-mediated inflammation contributes to structural valve degeneration.  Atherosclerotic risk factors (diabetes, smoking, hypercholesterolemia, metabolic syndrome) facilitate structural valve degeneration.  Modification of risk factors may help to reduce the incidence of structural valve degeneration  Transcatheter heart valve implantation (valve in valve) for failing surgical bioprosthesis is an emerging alternative to redo surgery Mylotte D, Lange R, Martucci G, Piazza N. Transcatheter heart valve implantation for failing surgical bioprostheses: technical considerations and evidence for valve-in-valve procedures. Heart 2013;99:960-7
    13. 13. Summary  Echocardiography with Doppler is the method of choice in the evaluation and follow up of patients with valve prostheses.  Knowledge of the prosthesis type and size is essential to compare to reference prosthesis Doppler values.  A postop discharge echo should always be performed to document individual baseline Doppler values.  The occurrence of a significant increase in gradient and/or new regurgitation points to prosthetic valve degeneration.  TEE should be performed to clarify mechanism of degeneration and exclude endocarditis in (sub)febrile patients.  Transcatheter valve-in-valve implantation may be a good option in the future for the management of bioprosthetic valve failure in high-risk patients.
    14. 14. Join the ESC Working Group on Valvular Heart Disease and take part in its activities ! Membership is FREE!
    1. A particular slide catching your eye?

      Clipping is a handy way to collect important slides you want to go back to later.

    ×